Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin L Cope

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Frontiers in Genetics|November 8, 2021
Interaction-Based Feature Selection Algorithm Outperforms Polygenic Risk Score in Predicting Parkinson's Disease StatusJustin L Cope, Hannes A Baukmann, Jörn E Klinger, et al.
Iscience|November 15, 2023
Exploring disease-causing traits for drug repurposing in critically ill COVID-19 patients: A causal inference approachHannes A Baukmann, Justin L Cope, Colin Bannard, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 14, 2025
Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical recordsHaraldur Þorsteinsson, Hannes A Baukmann, Hildur S Sveinsdóttir, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Frontiers in Genetics|November 8, 2021
Interaction-Based Feature Selection Algorithm Outperforms Polygenic Risk Score in Predicting Parkinson's Disease StatusJustin L Cope, Hannes A Baukmann, Jörn E Klinger, et al.
Iscience|November 15, 2023
Exploring disease-causing traits for drug repurposing in critically ill COVID-19 patients: A causal inference approachHannes A Baukmann, Justin L Cope, Colin Bannard, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 14, 2025
Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical recordsHaraldur Þorsteinsson, Hannes A Baukmann, Hildur S Sveinsdóttir, et al.
Pageof 1